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Background: Inflammation plays an important role in coronary artery disease from the initiation of endothelial
dysfunction to plaque formation to final rupture of the plaque. In this study, we investigated the potential
pathophysiological and clinical relevance of novel cytokines secreted from various cells including adipocytes,
endothelial cells, and inflammatory cells, in predicting coronary artery disease (CAD) in asymptomatic subjects with
type 2 diabetes mellitus.
Methods: We enrolled a total of 70 asymptomatic type 2 diabetic patients without a documented history of
cardiovascular disease, and determined serum levels of chemerin, omentin-1, YKL-40, and sCD26. We performed
coronary computed tomographic angiography (cCTA) in all subjects, and defined coronary artery stenosis≥ 50 % as
significant CAD in this study.
Results: Subjects were classified into two groups: patients with suspected coronary artery stenosis on cCTA (group
I, n = 41) and patients without any evidence of stenosis on cCTA (group II, n = 29). Group I showed significantly
higher YLK-40 levels and lower HDL-C levels than group II (p = 0.038, 0.036, respectively). Levels of chemerin,
omentin-1, and sCD26 were not significantly different between the two groups. Serum YKL-40 levels were positively
correlated with systolic/diastolic BP, fasting/postprandial triglyceride levels, and Framingham risk score. Furthermore,
YKL-40 levels showed moderate correlation with the degree of coronary artery stenosis and the coronary artery
calcium score determined from cCTA. In multivariate logistic analysis, after adjusting for age, gender, smoking
history, hypertension, and LDL-cholesterol, YLK-40 levels showed only borderline significance.
Conclusions: YKL-40, which is secreted primarily from inflammatory cells, was associated with several CVD risk
factors and was elevated in type 2 diabetic patients with suspected coronary artery stensosis on cCTA. These results
suggest the possibility that the inflammatory biomarker YKL-40 might be associated with coronary artery disease in
asymptomatic patients with type 2 diabetes mellitus.
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Prediction and early diagnosis of coronary heart disease
(CHD) facilitates appropriate intervention in the early
stages of this disease. Despite our growing understand-
ing of the pathophysiology of CHD in subjects with type
2 diabetes mellitus (T2D), predicting future CHD events
remains largely reliant upon evaluation of traditional risk
factors [1,2]. Even in apparently low- and intermediate-
risk individuals assessed by conventional risk scores, a
large number of diabetic subjects still experience cardio-
vascular disease (CVD) [3,4]. Therefore, novel biomar-
kers and predictive tools are required to facilitate
optimal intervention in patients with coronary artery
disease (CAD). An important feature of cardiometabolic
disease is nonspecific local inflammatory processes that
are accompanied by a low-grade systemic response [5].
Several studies in the past decade have investigated the
effects of cytokines produced from different cells of ori-
gin on the progression of CAD in patients with type 2
diabetes to detect occult CAD. Of the clinical trials, the
JUPITER trial of subjects with elevated high-sensitivity
C-reactive protein (hsCRP) levels demonstrated how a
biomarker can be used clinically to identify persons who
might benefit from aggressive statin therapy [3]. Unfor-
tunately, there was only a modest improvement in risk
prediction when hsCRP was added to standard risk fac-
tor models.
In this study, we investigated the potential patho-
physiological and clinical relevance of novel cytokines
secreted from various cells including adipocytes, endo-
thelial cells, and inflammatory cells in CAD prediction
in asymptomatic subjects with type 2 diabetes mellitus.
To do these, we selected four candidates biomarkers:
chemerin, omentin-1, YKL-40, and sCD26, and validated
subjects’ CAD status with coronary computed tomog-
raphy (CT).Methods
Study population
We cross-sectionally enrolled a total of 70 asymptomatic
type 2 diabetic patients older than 45 years old attending
the Diabetes Center of Severance Hospital. Exclusion
criteria were as follows: (1) chest pain or equivalent
symptoms according to the Rose questionnaire [6], (2)
documented history of atherosclerotic vascular disease
such as angina, myocardial infarction, cerebrovascular
disease, or peripheral artery occlusive disease, (3)
chronic kidney disease (creatinine> 1.5 mg/dL), (4)
plasma aspartate transaminase (AST) and/or alanine
transaminase (ALT) levels two-fold higher than the
upper limit of normal, (5) hematological and/or malig-
nant disease, and (6) previous history of radiocontrast-
induced anaphylaxis. This study was approved by theResearch Committee of Severance Hospital and written
informed consent was obtained from all participants.
Cardiac computed tomography protocol
Cardiac CT was performed using a 64-slice CT scanner
(Sensation 64; Siemens Medical Solutions, Erlangen,
Germany) as described previously [7]. Participants with
a resting heart rate above 65 beats/min received an oral
β-blocker (50 mg of metoprololtartate; Betaloc, Seoul,
Korea) 1 hr before examination. In addition, a 0.3 mg
sublingual dose of nitroglycerin was administrated just
before scanning. Before multidetector coronary com-
puted tomographic angiography (cCTA), a non-
enhanced prospective ECG-gated sequential scan was
performed to measure coronary artery calcification
(CAC) under the following conditions: rotation time of
330 ms, slice collimation of 0.6 mm, slice width of
3.0 mm, tube voltage of 120 kV, tube current of 50 mAs,
and table feed/scan of 18 mm. cCTA was performed
using retrospective ECG-gating with the following scan
parameters: rotation time of 330 ms, slice collimation of
64 × 0.6 mm, tube voltage of 100–120 kV, tube current
of 600–800 mAs depending on the patient’s weight, table
feed/scan of 3.8 mm, and pitch factor of 0.2. ECG-based
tube current modulation was applied to 65 % of the R-R
interval. A real-time bolus tracking method was used to
trigger scan initiation. The mean radiation dose for the
CAC scan and cCTA was 5.6 mSv (4.2–66.8 mSv) and
14.1 mSv (4.5–91.6 mSv), respectively. Contrast en-
hancement was achieved with 60 ml of Iopamidol
(370 mg of iodine/ml, Iopamiro; Bracco, Milan, Italy)
injected at 5 ml/s, followed by an injection of 30 ml of
mixed saline (contrast agent: saline = 3: 7) and 30 ml of
saline at 5 ml/s. A real-time bolus tracking method was
used to trigger scan initiation. Two experienced radiolo-
gists prospectively and independently reviewed the
cCTA images of the 70 patients. Differences in assess-
ment were resolved by consensus. Each reader was
blinded to the results of other examinations and clinical
data.
Risk factor analysis and laboratory assessments
We measured the patients’ height and weight to calcu-
late their body-mass index (BMI). Blood pressure was
measured twice with a mercury sphygmomanometer on
the right upper arm after resting for at least 10 minutes
in a seated position, and we used the average values of
systolic and diastolic blood pressures. All individuals
provided details regarding demographics, medical his-
tory, and medication profile. Subjects who were current
or former smokers were defined as smokers. We investi-
gated medication histories including use of insulin, oral
hypoglycemic agents, statins, angiotensin receptor block-
ers (ARBs), angiotensin-converting enzyme (ACE)
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with high total cholesterol (>200 mg/dl), high low-density
lipoprotein cholesterol (LDL-cholesterol) (>160 mg/dl),
low high-density lipoprotein cholesterol (HDL-cholesterol)
(<35 mg/dl for men, <40 mg/dl for women), and/or high
triglycerides (>150 mg/dL), or current use of lipid-
lowering therapy were coded as having dyslipidemia.
Hypertension was defined as a self-reported history of
hypertension and/or a history of antihypertensive medica-
tion use or a systolic blood pressure of 140/90 mmHg
once or more at the time of the visit.
Blood samples were collected from subjects after an
overnight fast. All participants underwent laboratory
analyses, including determination of fasting plasma glu-
cose levels by the glucose oxidase method, total choles-
terol, triglyceride, HDL-cholesterol, LDL-cholesterol,
blood urea nitrogen, creatinine, AST, and ALT using a
routine Hitachi 7600 autoanalyzer (Hitachi Instruments
Service, Tokyo, Japan), glycated hemoglobin (HbA1c) by
high-performance liquid chromatography (HPLC) using
a Variant II Turbo system (Bio-Rad Laboratories,
Hercules, CA), glycated albumin (GA) by an albumin-
specific proteinase assay, ketamine oxidase, albumin
assay reagents (LUCICA GA-L, Asahi Kasei Pharma Co.,
Tokyo, Japan) using a Hitachi 7699 Pmoduleautoanaly-
zer, and hsCRP by a latex-enhanced immunoephelo-
metric method using a BN II analyzer (Dade Behring,
Newarkand, DE). Serum insulin levels were measured in
duplicate using an immunoradiometric assay (IRMA)
method (Beckman Coulter, Fullerton, CA). Insulin resist-
ance was assessed by using the homeostasis model as-
sessment – insulin resistance (HOMAIR) equation as
follows: HOMAIR = (fasting insulin (in microunits per
milliliter) × fasting serum glucose (in millimoles per
liter)/22.5). Blood samples were collected 120 min after
food intake for glucose and triglyceride analyses.
The separated sera were stored at −70 °C until che-
merin (Millipore, Bedford, MA), omentin-1 (Millipore,
Bedford, MA), YKL-40 (Quidel, San Diego, CA), and
sCD26 (Bender MedSystems, Vienna, Austria) levels
could be measured using commercially available ELISA
kits according to the manufacturers’ instructions. The
intra- and inter-assay variation was 5.0 % and 4.0 % for
the chemerin ELISA, 1.5 % and 5.8 % for the omentin-1
ELISA, 6.0 % and 6.6 % for the YKL-40 ELISA, and
4.6 % and 9.1 % for the sCD26 ELISA, respectively.
Statistical analysis
All statistical analyses were performed with PASW sta-
tistics software (version 18.0; SPSS Inc., Chicago, IL).
Continuous variables with a normal distribution are
expressed as means ± SD unless otherwise indicated. A P
value< 0.05 was considered statistically significant.
Intergroup differences in baseline characteristics wereanalyzed by independent t-tests or the chi-square test.
Differences among three groups according to the sever-
ity of stenosis were tested using one-way ANOVA and
subsequent post hoc analyses (Tukey's HSD). Pearson’s
correlation coefficients were calculated to examine the
relationships between serum YKL-40 levels and meta-
bolic and cardiovascular variables. Multivariate logistic
regression analysis was used to determine the factors
associated with suspected CAD on cCTA in patients
with diabetes.Results
A total of 70 subjects (28 men and 42 women; mean age
59.6 ± 6.3 years) were enrolled in this study. The mean
duration of diabetes was 7.2 ± 1.2 years. The levels of
serum HbA1c and GA were 7.29 ± 1.22, and 19.2 ± 6.1 %,
respectively. The mean BMI of the study subjects was
26.0 ± 3.4 kg/m2.
As outlined in the Duke coronary artery index [8,9],
we defined the degree of stenosis as significant stenosis
(≥ 50 %), minimal stenosis (< 50 %), or normal based on
the lumen diameter of diseased vessels. According to the
degree of stenosis on cCTA, we divided the patients into
two groups: those with suspected CAD (n = 41) and
those without any evidence of CAD (n = 29). And we
consulted with a cardiologist about the patients with sig-
nificant CAD (≥ 50 % stenosis), and invasive coronary
angiography (ICA) was recommended in 10 patients
who showed radiological and clinical signs of CAD. Nine
patients eventually underwent ICA and five patients
received revascularization (one coronary artery bypass
graft and four percutaneous coronary interventions).
The baseline clinical characteristics of the group of
type 2 diabetic patients with suspected CAD and those
with no evidence of CAD are shown in Table 1. There
were no significant differences between the two groups
in age, gender, BMI, diabetes duration, glucose para-
meters including fasting/postprandial glucose, HbA1c,
GA, and HOMAIR, lipid profiles or hsCRP levels. Sys-
tolic blood pressure tended to be higher in the subjects
with suspected CAD compared to those with no evi-
dence of CAD, although it did not reach a statistical sig-
nificance (131 ± 18 vs. 122 ± 17 mmHg, p = 0.066). There
were no significant differences between the two groups
in conventional coronary risk factors such as prevalence
of hypertension, dyslipidemia, family history of prema-
ture CAD, smoking history, or Framingham risk score
(FRS). The history of medication use including insulin,
oral hypoglycemic agents, statins, and anti-hypertensive
agents was similar in both groups. However, the coron-
ary artery calcium score (CACS) was much higher in
patients with CAD than those without CAD (206 ± 342
vs. 3 ± 13, p= 0.003).








Age (years) 60 ± 5 58 ± 6 0.237
Male (n,%) 19 (46.3) 9 (31.0) 0.149
Body-mass index (kg/m2) 25.7 ± 3.3 26.4 ± 3.6 0.468
SBP (mmHg) 131± 18 122 ± 17 0.066
DBP(mmHg) 74 ± 10 71 ± 8 0.305
Diabetes duration (years) 9.1 ± 7.1 8.7 ± 6.1 0.813
Hypertension (n,%) 29 (70.7) 19 (65.5) 0.418
Dyslipidemia (n,%) 18 (62.1) 27 (65.9) 0.47
Family history of CAD (n,%) 25 (61.0) 17 (58.6) 0.519
Smoking Hx (n,%) 0.064
Never smoker 29 (70.7) 25 (86.2)
Ex-smoker 4 (9.8) 3 (10.3)
Current smoker 8 (19.5) 1 (3.4)
FPG (mg/dL) 132± 46 136 ± 41 0.718
PPG-2 hrs (mg/dL) 219± 104 196 ± 90 0.331
HbA1c (%) 7.49 ± 1.24 7.14 ± 1.19 0.398
GA (%) 19.7 ± 6.8 18.4 ± 4.9 0.362
hsCRP (mg/dL) 2.75 ± 5.39 1.83 ± 2.23 0.335
Total cholesterol (mg/dL) 175± 50 166 ± 43 0.414
LDL cholesterol (mg/dL) 100± 37 94 ± 39 0.585
HDL cholesterol (mg/dL) 45 ± 11 46 ± 12 0.745
TG (mg/dL) 130± 76 118 ± 44 0.41
Postprandial TG (mg/dL) 124± 60 112 ± 43 0.352
HOMAIR 5.25 ± 6.51 4.18 ± 3.10 0.364
Framingham risk score (FRS) 7.3 ± 5.6 5.2 ± 6.3 0.18
CACS 206± 342 3 ± 13 0.003
Chemerin (ng/mL) 201.3 ± 82.3 193.1 ± 75.9 0.674
Omentin (ng/mL) 104.4 ± 29.4 106.4 ± 23.5 0.767
YKL-40 (ng/mL) 148.6 ± 82.3 96.7 ± 73.0 0.013
sCD26 (ng/mL) 381.5 ± 399.4 332.0 ± 188.9 0.494
Insulin (%) 12 (29.3) 9 (31.0) 0.54
Sulfonylurea (%) 18 (43.9) 14 (48.3) 0.453
Metformin (%) 29 (70.7) 24 (82.8) 0.192
Thiazolidinedione (%) 12 (29.3) 7 (24.1) 0.423
ARB or ACE inhibitors (%) 26 (63.4) 12 (41.4) 0.057
Calcium channer blockers (%) 10 (24.4) 6 (20.7) 0.474
Beta blockers (%) 5 (12.2) 2 (6.9) 0.381
Statins (%) 22 (53.7) 15 (51.7) 0.533
DM, diabetes mellitus; CAD, coronary artery disease; SBP, systolic blood
pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; PPG-2 hrs,
postprandial plasma glucose-2 hrs; HbA1c, glycated hemoglobin; GA, glycated
albumin; hsCRP, high-sensitive C-reactive protein; LDL, ligh-density lipoprotein;
HDL, high-density lipoprotein; TG, triglycerides; HOMAIR, homeostasis model
assessment– insulin resistance; CACS, coronary artery calcium score; ARB,
angiotensin receptor blocker; ACE, angiotensin converting enzyme.
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evaluated. Of the four candidates, only YKL-40 showed
a statistical difference between the two groups
(148.6 ± 82.3 vs. 96.7 ± 73.0 ng/mL, p= 0.013). The other
candidate biomarkers had comparable levels in the two
groups (chemerin 201.3 ± 82.3 vs. 193.1 ± 75.9 ng/mL,
omentin-1 104.4 ± 29.4 vs. 106.4 ± 23.5 ng/mL, and
sCD26 381.5 ± 399.4 vs. 332.0 ± 188.9 ng/mL, p= 0.674,
p= 0.767, and p= 0.494, respectively). The levels of cyto-
kines were further classified according to the degree of
coronary artery stenosis on cCTA (Figure 1). This sub-
analysis revealed that serum YKL-40 levels were higher
in patients with coronary artery stenosis than patients
with no evidence of stenosis, and were further increased
in patients with stenosis ≥ 50 % (96.7 ± 73.0 vs.
133.5 ± 81.9 vs. 171.3 ± 94.7 ng/mL, p= 0.017). Serum
chemerin and omentin-1 levels were similar among 3
groups (p= 0.584, p= 0.637, respectively). sCD26 levels
tended to be higher in patients with ≥ 50 % stenosis
compared to patients with no evidence of stenosis or
< 50 % stenosis; however, these differences were not sta-
tistically significant (459.2 ± 589.5 vs. 332.0 ± 188.9 ng/
mL, 459.2 ± 589.5 vs. 331.7 ± 205.3 ng/mL, p= 0.44,
p= 0.453, respectively).
Next, we evaluated the correlation between serum
YKL-40 levels and various metabolic and cardiovascular
parameters (Table 2). There were significant but weak
correlations between YKL-40 concentrations, systolic/
diastolic blood pressure, and fasting/postprandial trigly-
ceride levels. YKL-40 levels were positively correlated
with several cardiovascular parameters including Fra-
mingham risk score, degree of coronary artery stenosis
on cCTA, and CACS on cardiac CT. However, serum
YKL-40 concentrations did not correlate significantly
with fasting insulin, LDL-cholesterol, HDL-cholesterol,
hsCRP levels, BMI, or HOMAIR.
To determine the factors that were predictive of cor-
onary artery stenosis in the subjects with asymptomatic
type 2 diabetes, we performed univariate and multivari-
ate logistic analyses. Three statistical models with differ-
ent independent variables were used. We entered non-
modifiable and modifiable risk variables in models 1 and
2, respectively. Serum YKL-40 showed only borderline
significance after adjusting for age, gender, smoking his-
tory, hypertension, and LDL-cholesterol level. After ad-
justment for hsCRP, YKL-40 still showed borderline
significance for predicting suspected CAD in patients
with type 2 diabetes mellitus (Table 3).
Discussion
In contrast to the characteristics of type 1 diabetes melli-
tus, an etiologic chronic proinflammatory state is
thought to be involved in the pathophysiology of T2D,
ultimately resulting in atherosclerotic changes [10]. Due
Figure 1 Serum levels of chemerin, omentin-1, YKL-40, and sCD26 according to the severity of coronary artery stenosis on cCTA in
patients with type 2 diabetes mellitus.
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lar actions, cross-talk between adipose tissue, the im-
mune system, and the vascular wall in T2D, several
novel biomarkers and predictive tools to aid in the
appropriate intervention of CAD have been proposed
[11]. Adipocytes enriched by pathological accumula-
tion or de novo synthesis secrete a host of mediators
called adipokines. Adipokines produced in obesity
regulate inflammation by both overproduction of
proinflammatoryadipokines and lower production of
anti-inflammatory adipokines, and regulate vascularTable 2 Metabolic and cardiovascular parameters and
their correlations with serum YKL-40 levels
Correlation coefficient P-value
SBP (mmHg) 0.269 0.017
DBP (mmHg) 0.287 0.011
Fasting triglycerides (mg/dL) 0.234 0.039
Postprandial triglycerides (mg/dL) 0.386 < 0.001
Framingham risk score (FRS) 0.289 0.01
Degree of coronary artery
stenosis on cCTA (%)
0.407 0.001
CACS 0.407 < 0.001
SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglycerides;
cCTA; coronary computed tomographic angiography; CACS, coronary artery
calcium score.tone by producing vasorelaxants and vasoconstrictors
[12]. In addition, cytokines secreted from inflamma-
tory or endothelial cells play a key role in the inter-
organ crosstalk between metabolic disease and vascular
disease.
In this study, we investigated the clinical relevance of
novel biomarkers secreted from adipocytes, inflamma-
tory cells, and/or endothelial cells in Korean subjects
with T2D. We performed cardiac CT and adopted cCTA
to validate the presence of CAD. There were three mainTable 3 Univariate and multivariate logistic regression
analyses for suspected CAD on cCTA in type 2 diabetic
patients
Odds ratio (95 % CI) p-value
Univariate 1.009 (1.001 - 1.016) 0.018
Multivariate
Model 1* 1.007 (1.000 - 1.015) 0.047
Model 2† 1.007 (1.000 - 1.015) 0.054
Model 3{ 1.008 (1.000 - 1.015) 0.048
CAD, coronary artery disease; cCTA; coronary computed tomographic
angiography; CI, confidence interval.
* Adjusted for age and gender.
† Adjusted for age, gender, smoking history, hypertension, and low density
lipoprotein cholesterol.
{ Adjusted for age, gender, smoking history, hypertension, low density
lipoprotein cholesterol and high-sensitive C-reactive protein.
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no evidence of CAD on cCTA, the level of serum YKL-
40, which is secreted mainly by inflammatory cells, was
markedly increased in subjects with suspected CAD.
Second, serum YKL-40 levels were positively correlated
with several metabolic and cardiovascular parameters.
Third, after adjusting for other cardiovascular risk fac-
tors and hsCRP, which is a traditional inflammatory mar-
ker, YKL-40 showed some borderline significance for
predicting any degree of coronary artery stenosis in sub-
jects with T2D.
YKL-40 has been implicated in previous studies in dia-
betes and atherosclerosis. Inflammation is known to be a
contributing factor to T2D, and the numbers of inflam-
matory cells within the visceral adipose tissue are
increased. Several recent studies have documented that
YKL-40 levels were elevated in both type 1 and type 2
diabetic subjects independent of BMI [13,14]. Consistent
with other studies, we found a positive correlation be-
tween YKL-40 levels and several metabolic parameters,
such as fasting/postprandial triglyceride levels in this
study.
In the initiation and progression of atherosclerosis,
activated macrophages take up lipids and then these
lipid-rich macrophages secret inflammatory mediators
that stimulate VSMC migration and proliferation [15],
resulting in atherosclerosis. It is known that YKL-40 is
secreted by activated macrophages and neutrophils in
different tissues with inflammation, vascular smooth
muscle cells (VSMC), cancer cells, and arthritic chon-
drocytes [16]. In this regard, YKL-40 may be involved in
the early stage of atherosclerosis and CAD. So we cate-
gorized the asymptomatic type 2 diabetic patients into
two groups – those with any degree of stenosis in coron-
ary artery on cCTA (suspected CAD) and those with
completely normal coronary artery on cCTA (no evi-
dence of CAD). In our study, we did not find any signifi-
cant association between suspected CAD and hsCRP, the
most widely used and evaluated inflammatory biomarker
for cardiovascular diseases. YKL-40 levels, however, were
significantly higher in patients with suspected CAD than
those with no evidence of CAD. YKL-40 is produced lo-
cally by inflammatory cells, however, hsCRP is produced
by hepatocyte in response to high circulating cytokine
levels. Taken together, YKL-40 might be more sensitive
marker than hsCRP for predicting suspected CAD in
type 2 diabetic patients. Because few studies have been
conducted on YKL-40 as a novel marker for predicting
occult CAD in asymptomatic subjects with normal glu-
cose tolerance or diabetes mellitus, our results make a
novel contribution to the clinical relevance of YKL-40 in
asymptomatic type 2 diabetic patients.
There is a controversy in the association between
serum YKL-40 level and the severity of atherosclerosis.In our study, serum YKL-40 level was correlated with
the degree of coronary artery stenosis on cCTA, and
increased along with the degree of stenosis. However, re-
cent study concluded that circulating YKL-40 was not
specifically related to the size of stenosis [17]. Another
study investigating the role of YKL-40 in patients with
peripheral arterial disease showed that severity of ath-
erosclerosis is associated with higher YKL-40 levels [18].
These conflicting results may be due to differences in
the study participants and diagnostic modality for evalu-
ation of coronary artery and severity of atherosclerosis.
Understanding the action mechanism of YKL-40 in ath-
erosclerosis could help clarify the clinical meaning of
serum YKL-40.
We investigated chemerin in this study as it is a proin-
flammatoryadipokine that modulates chemotaxis and
activates macrophages [19], thereby facilitating the de-
velopment of atherosclerosis and CAD [20,21]. Also, we
chose to evaluate omentin-1 as it is an anti-
inflammatory molecule [22]. Yooet al. showed that cir-
culating omentin-1 levels were decreased in patients
with T2D compared to normal glucose controls, and in-
dependently correlated with arterial stiffness and carotid
plaque after adjusting for other risk factors in type 2 dia-
betic patients [23]. However, the serum levels of che-
merin and omentin-1 were not significantly associated
with the severity of coronary artery stenosis in this study
(Figure 1). Both markers are secreted from adipocytes,
and epicardial adipose tissue may have direct effects on
coronary artery atherosclerosis due to its close proximity
to coronary artery [24]. So, locally produced adipokines
by EAT rather than circulating level might affect the
process of atherosclerosis. Previous study has shown that
the mRNA and protein expressions of chemerin were
significantly higher in epicardial adipose tissue from
patients with CAD compared to that from normal con-
trol, however, there was no significant differences in cir-
culating chemerin level between two groups [25]. In
addition, adipose tissues are known to secret several adi-
pokines that have an important role in the initiation of
insulin resistance [26] or endothelial dysfunction [27],
measurement of visceral adipose mass and levels of
other adipokines, such as adiponectin or leptin, could
help elucidate why these two markers did not predict
CAD in our study [28,29].
sCD26 is a dipeptidyl peptidase-4 (DPP-4) that is ubi-
quitously expressed in epithelial and endothelial cells
and that circulates in plasma [30]. The main source of
this enzyme is thought to be microvascular endothelial
cells [31]. Although a recent study demonstrated that
sCD26 might impair insulin sensitivity in both an auto-
crine and paracrine fashion, and has a role in linking
adipose tissue and metabolic syndrome [32], few clinical
studies have examined the association between sCD26
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our study, sCD26 levels tended to increase in patients
with significant CAD (coronary artery stenosis≥ 50 % on
cCTA). Although this finding was not statistically signifi-
cant in our study, it is possible that increased sCD26
levels may be associated with the progression of
atherosclerosis.
Further studies are required to validate our findings
due to several limitations of our study. First, we only
investigated a relatively small number of cases. Second,
because of the inherent weaknesses of cross-sectional
design, we could not determine if there was a causal re-
lationship between YKL-40 and the initiation and pro-
gression of CAD. Lastly, we did not measure the levels
of the novel markers we examined in age-matched con-
trols or in normal glucose-tolerant subjects with CAD.
However, serum YKL-40 levels have been shown to be
higher in patients with type 1 and type 2 diabetes melli-
tus than control subjects with normal glucose tolerance
[13,14].
Conclusions
In conclusion, we evaluated whether four novel cyto-
kines (chemerin, omentin-1, YKL-40, and sCD26)
secreted from different origins in type 2 diabetic patients
were associated with CAD, and found that only serum
YKL-40 levels were markedly elevated in patients with
type 2 diabetes patients with suspected CAD on cCTA
compared to patients with no evidence of CAD. Further-
more, YKL-40 levels were positively correlated with the
severity of CAD and various metabolic parameters.
However, after adjusting for other cardiovascular risk
factors, YKL-40 showed only borderline significance.
Based on these results, we suggest the possibility that
the inflammatory biomarker YKL-40 might be associated
with coronary artery disease in asymptomatic patients
with type 2 diabetes mellitus. However, further large-
scale clinical studies are warranted.
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